Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:lup.lub.lu.se:99331fc5-8b3d-4584-bcdd-47392414fe4c" > Dendritic cell vacc...

1 of 1
Previous record
Next record
To hitlist

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Anguille, Sébastien (author): University of Antwerp,Antwerp University Hospital

Van De Velde, Ann L. (author): University of Antwerp,Antwerp University Hospital

Smits, Evelien L. (author): University of Antwerp

Van Tendeloo, Viggo F. (author): University of Antwerp

Juliusson, Gunnar (author): Lund University,Lunds universitet,Skåne University Hospital

Cools, Nathalie (author): University of Antwerp

Nijs, Griet (author): University of Antwerp,Antwerp University Hospital

Stein, Barbara (author): Antwerp University Hospital,University of Antwerp

Lion, Eva (author): University of Antwerp

Driessche, Ann Van (author): University of Antwerp,Antwerp University Hospital

Vandenbosch, Irma (author): Antwerp University Hospital

Verlinden, Anke (author): Antwerp University Hospital,University of Antwerp

Gadisseur, Alain P. (author): Antwerp University Hospital,University of Antwerp

Schroyens, Wilfried A. (author): Antwerp University Hospital,University of Antwerp

Muylle, Ludo (author): University of Antwerp,Antwerp University Hospital

Vermeulen, Katrien (author): Antwerp University Hospital

Maes, Marie Berthe (author): Antwerp University Hospital

Deiteren, Kathleen (author): Antwerp University Hospital

Malfait, Ronald (author): Antwerp University Hospital

Gostick, Emma (author): Cardiff University

Lammens, Martin (author): Antwerp University Hospital

Couttenye, Marie M. (author): Antwerp University Hospital

Jorens, Philippe (author): Antwerp University Hospital

Goossens, Herman (author): University of Antwerp,Antwerp University Hospital

Price, David A. (author): Cardiff University

Ladell, Kristin (author): Cardiff University

Oka, Yoshihiro (author): Osaka University

Fujiki, Fumihiro (author): Osaka University

Oji, Yusuke (author): Osaka University

Sugiyama, Haruo (author): Osaka University

Berneman, Zwi N. (author): University of Antwerp,Antwerp University Hospital

show less...

(creator_code:org_t)

American Society of Hematology, 2017
2017
English 9 s.
In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 130:15, s. 1713-1721

Related links:: http://dx.doi.org/10...; show more...; https://ashpublicati...; https://lup.lub.lu.s...; https://doi.org/10.1...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

Relapse is a major problem in acute myeloid leukemia (AML) and adversely affects survival. In this phase 2 study, we investigated the effect of vaccination with dendritic cells (DCs) electroporated with Wilms’ tumor 1 (WT1) messenger RNA (mRNA) as postremission treatment in 30 patients with AML at very high risk of relapse. There was a demonstrable antileukemic response in 13 patients. Nine patients achieved molecular remission as demonstrated by normalization of WT1 transcript levels, 5 of which were sustained after a median follow-up of 109.4 months. Disease stabilization was achieved in 4 other patients. Five-year overall survival (OS) was higher in responders than in nonresponders (53.8% vs 25.0%; P 5 .01). In patients receiving DCs in first complete remission (CR1), there was a vaccine-induced relapse reduction rate of 25%, and 5-year relapse-free survival was higher in responders than in nonresponders (50% vs 7.7%; P < .0001). In patients age £65 and >65 years who received DCs in CR1, 5-year OS was 69.2% and 30.8% respectively, as compared with 51.7% and 18% in the Swedish Acute Leukemia Registry. Long-term clinical response was correlated with increased circulating frequencies of polyepitope WT1-specific CD81 T cells. Long-term OS was correlated with interferon-g1 and tumor necrosis factor-a1 WT1-specific responses in delayed-type hypersensitivity-infiltrating CD81 T lymphocytes. In conclusion, vaccination of patients with AML with WT1 mRNA-electroporated DCs can be an effective strategy to prevent or delay relapse after standard chemotherapy, translating into improved OS rates, which are correlated with the induction of WT1-specific CD81 T-cell response. This trial was registered at www.clinicaltrials.gov as #NCT00965224.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

Blood (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Hematology

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

Articles in the publication: Blood

By the university: Lund University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se